DT MedTech
DT MedTech, LLC develops and distributes the Hintermann Series total ankle replacement systems (H2 semi-constrained and H3 mobile-bearing) and the Kalix II subtalar arthroereisis implant, serving orthopedic foot and ankle surgeons and hospitals across 30+ countries through a distributor-based model.
- Company typePrivate
- Founded2016
- HeadquartersMcminnville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What DT MedTech does
DT MedTech, LLC is a privately held medical device company headquartered in McMinnville, Tennessee, that develops and distributes lower extremity orthopedic products, principally the Hintermann Series total ankle replacement (TAR) systems. Founded in 2016 to commercialize the intellectual property of Prof. Beat Hintermann (Chairman of Orthopaedics and Traumatology at Kantonsspital Baselland, Switzerland), the company's core portfolio consists of the H3—a non-constrained, mobile-bearing, three-component TAR system (cobalt chromium tibial component, anatomically shaped talar component, UHMWPE mobile bearing insert) with plasma-spray titanium and hydroxyapatite coatings for bone ingrowth—and the H2, a semi-constrained two-component TAR system with anterior/neutral/posterior PE inlay offsets. Both systems use a single instrument set and surgical approach, enabling surgeons to select mobile-bearing or semi-constrained options intraoperatively. The portfolio also includes the Kalix II subtalar arthroereisis implant for flatfoot deformities. Clinical evidence cited includes 88% survivorship at seven years and 95.9% patient satisfaction at five years for the H3, with 20,000+ H3 implantations globally since 2000 and a published 684-patient survivorship analysis.
The company sells its products through a distribution-based go-to-market model with 50+ US distributors, 25+ international distribution partners, and 300+ field representatives, supported by logistics partners HealthLink Europe International (US) and HealthLink Europe BV (Netherlands). End customers are orthopedic foot and ankle surgeons and the hospitals/surgical centers performing TAR procedures, with marketing concentrated on clinical publications, surgeon training programs, and peer-to-peer education rather than consumer advertising. Regulatory milestones include CE marking (August 2016), FDA 510(k) clearance for H2 (November 2017), and FDA Premarket Approval for H3 (June 2019); products are registered in 30+ countries. Pricing is not publicly disclosed and is negotiated through surgeon/hospital procurement channels.
Since July 2020, DT MedTech has operated as a wholly owned subsidiary of Vilex, LLC, a member of the Squadron Capital family of businesses, with international operations conducted through DT MedTech International Limited (Ireland). The Vilex acquisition integrated the Hintermann Series with Vilex's US sales organization, expanding US commercial coverage. Revenue is generated through hardware sales of implants and instrumentation, and the company maintains its own quality system for manufacturing.
DT MedTech firmographics
Firmographics- Name
- DT MedTech
- Legal name
- DT MedTech, LLC
- Website
- https://dtmedtech.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- DT MedTech, LLC develops and distributes the Hintermann Series total ankle replacement systems (H2 semi-constrained and H3 mobile-bearing) and the Kalix II subtalar arthroereisis implant, serving orthopedic foot and ankle surgeons and hospitals across 30+ countries through a distributor-based model.
- Ownership category
- akta.pro rank
DT MedTech industry classification
Industry- Product category
- Orthopedic Implants
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)
- akta.pro secondary industries
- Foot & Ankle (HLAKALAG), Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)
Keywords
Where DT MedTech is headquartered
LocationHeadquarters
- HQ city
- Mcminnville
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
DT MedTech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel, Infrastructure
Revenue model
- Medical Device Sales: DT MedTech generates revenue through the sale of total ankle replacement implants and instrumentation. The company sells directly through its US distribution network and internationally through HealthLink Europe BV and other distributors. Products include Hintermann Series H2 and H3 total ankle replacement systems, along with revision components.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
DT MedTech product offering
Product offeringCore offering
DT MedTech manufactures and distributes the Hintermann Series total ankle replacement (TAR) systems, including the H3 mobile-bearing three-component system and the H2 semi-constrained two-component system, along with the Kalix II subtalar arthroereisis implant. Both TAR systems share a single surgical instrument set, enabling orthopedic foot and ankle surgeons to choose the optimal implant design intraoperatively for primary or revision ankle replacement procedures. The company sells directly to hospitals and surgical centers through a network of distributors in the US and internationally, with FDA PMA approval (H3) and 510(k) clearance (H2) in the United States and CE marking across Europe and other international markets.
Product overview
DT MedTech, LLC offers a portfolio of lower extremity medical devices, primarily the Hintermann Series Total Ankle Replacement Systems. The core products are the Hintermann Series H3® (a three-piece, mobile-bearing, non-constrained TAR system) and the Hintermann Series H2® (a two-piece, semi-constrained TAR system). Both systems utilize a single instrument set and surgical approach, allowing surgeons to choose between mobile-bearing and semi-constrained options for primary and revision total ankle replacement procedures. The portfolio also includes the Kalix® II subtalar arthroereisis implant for treating flatfoot deformities. All products were developed by Prof. Beat Hintermann and the company operates under Vilex, LLC as a wholly owned subsidiary following the 2020 acquisition.
Differentiator
Problem solved
Functional benefit
Brands
- Hintermann Series H2: Two-piece, semi-constrained total ankle replacement system indicated for cemented use in the US and non-cemented use outside the US. Used for primary ankle replacement and revision surgery.
- Hintermann Series H3
- Kalix II
Products and services
- Hintermann Series H3 Total Ankle Replacement System A three-component, non-constrained, mobile-bearing total ankle replacement system consisting of a cobalt chromium tibial component, anatomically-shaped talar component, and ultra-high molecular weight polyethylene (UHMWPE) mobile bearing insert. Indicated for primary osteoarthritis, post-traumatic osteoarthritis, and arthritis secondary to inflammatory disease. Features Plasma Spray Titanium and Hydroxyapatite coating for non-cemented use and optimal bone ingrowth. Available in seven sizes with PE inlay in four thicknesses. Used by orthopedic foot and ankle surgeons performing primary TAR procedures.
- Hintermann Series H2 Total Ankle Replacement System A two-component, semi-constrained total ankle replacement system consisting of a talar component, tibial assembly component (tibial slide and tray), and PE inlay assembly component. Designed for cemented use in the US and non-cemented use outside the US. Indicated for primary or revision surgery of ankle joints damaged by systemic, primary, or secondary arthritis. Features anterior, neutral, and posterior offset options for alignment reconstruction. Used by orthopedic foot and ankle surgeons who prefer a semi-constrained design for patients with ankle instability.
- Kalix II Subtalar Arthroereisis Implant A subtalar arthroereisis implant used to treat flatfoot deformities. Part of the Hintermann Series lower extremity product portfolio acquired by DT MedTech. Used by orthopedic foot and ankle surgeons for pediatric and adult flatfoot correction procedures.
Quantifiable outcome
- 88% survivorship at 7 years post-implantation for H3 system
- +3 more outcomes
Companies that use DT MedTech
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
DT MedTech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
DT MedTech partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Vilex LLCcoreVilex LLC, a member of Squadron Capital family of businesses, acquired DT MedTech LLC in July 2020. DT MedTech became a wholly owned subsidiary of Vilex. The acquisition combined Vilex's US market presence with DT MedTech's globally-renowned Hintermann Series product portfolio, creating a global leader in lower extremity surgical solutions. Vilex now supports Hintermann Series products through its sales organization.
- HealthLink Europe BVcoreHealthLink Europe BV handles logistics and distribution for DT MedTech products outside the US from their Netherlands location (De Tweeling 20-22, 5215 MC's-Hertogenbosch). Handles majority of logistics for products in approved countries including all EU markets.
- HealthLink Europe InternationalcoreHealthLink Europe International handles US logistics and distribution from its US headquarters in Raleigh, NC. Handles DT MedTech product distribution within the United States, including H2 and H3 sales and distribution.
- Professor Beat HintermanncoreProf. Beat Hintermann, Chairman of the Clinic for Orthopaedics and Traumatology at Kantonsspital Baselland in Liestal, Switzerland, developed the Hintermann Series H3 and H2 TAR systems. He continues as a key collaborator and inventor, with over 20 years of clinical experience. He remains involved in product development and surgeon training.
- M Squared AssociatesminorM Squared Associates served as advisors to DT MedTech in regulatory processes, including FDA PMA approval for H3 and 510(k) clearance for H2.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
DT MedTech competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights6 records
Customer concentration
DT MedTech social profiles
Digital presenceDT MedTech compliance and trust
Trust signalCompliance2 records
DT MedTech financial estimates
Financial estimateRevenue estimate
Valuation estimate
DT MedTech leadership team
Management profileNumber of profiles
Profiles1 record
DT MedTech subsidiaries and ownership
Company hierarchySubsidiaries1 record
DT MedTech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DT MedTech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DT MedTech
What does DT MedTech do?
DT MedTech manufactures and distributes the Hintermann Series total ankle replacement (TAR) systems, including the H3 mobile-bearing three-component system and the H2 semi-constrained two-component system, along with the Kalix II subtalar arthroereisis implant. Both TAR systems share a single surgical instrument set, enabling orthopedic foot and ankle surgeons to choose the optimal implant design intraoperatively for primary or revision ankle replacement procedures. The company sells directly to hospitals and surgical centers through a network of distributors in the US and internationally, with FDA PMA approval (H3) and 510(k) clearance (H2) in the United States and CE marking across Europe and other international markets.
Is DT MedTech a public or private company?
DT MedTech is a private company. It is classified as private equity controlled and is currently acquired.
When was DT MedTech founded?
DT MedTech was founded in 2016. It employs 11 to 50 people.
Where is DT MedTech based?
DT MedTech is headquartered in Mcminnville, United States, in the North America region.
How does DT MedTech make money?
One revenue line is on record: medical Device Sales.
Does DT MedTech have an API?
No public API is recorded for DT MedTech.
What industry is DT MedTech in?
DT MedTech's product category is Orthopedic Implants. Its primary akta.pro industry code is HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle), with a secondary code of HLAKALAG, Foot & Ankle. Its NAICS code is 339113 and its SIC code is 3842.